Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 4/20 | 0.47 |
| ▸ | CNR1 | P21554 | 8/20 | 0.46 |
| ▸ | TGM2 | P21980 | 6/20 | 0.40 |
| ▸ | F13A1 | P00488 | 5/20 | 0.40 |
| ▸ | TGM1 | P22735 | 3/20 | 0.40 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4274049 | 0.81 | STS (0.60) | STSCNR1TGM2F13A1TGM1 | |
| SCHEMBL16899 | 0.81 | ALDH1A1 (0.49) | STSTGM2F13A1TGM1 | |
| SCHEMBL17670 | 0.74 | PKM (0.52) | — | |
| SCHEMBL17671 | 0.74 | TGM2 (0.34) | TGM2F13A1TGM1TGM3 | |
| SCHEMBL25422301 | 0.70 | USP2 (0.47) | — | |
| SCHEMBL3838166 | 0.69 | ALDH1A1 (0.40) | STS | |
| SCHEMBL31218507 | 0.69 | CHRM2 (0.44) | — | |
| SCHEMBL13239843 | 0.69 | POLB (0.47) | STSCNR1 | |
| SCHEMBL5253160 | 0.69 | POLB (0.70) | STSCNR1TGM2F13A1TGM1 | |
| SCHEMBL5729645 | 0.68 | F10 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, RRM1 | STS 125/4885CNR1 499/4885TGM2 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.